Search for a trial

A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (HD)

The primary objective of TRIHEP 3 is to evaluate the efficacy of triheptanoin in (i) increasing the short term energy response in the metabolic profile of the brain of early affected HD patients, as captured by 31P-MRS, and (ii) slowing atrophy in…

A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington*s Disease

The primary objective of this study is to assess the efficacy of pridopidine 67.5 to 112.5 mg twice daily (bid) on motor impairment in patients with HD after 26 weeks of treatment using the Unified Huntington*s Disease Rating Scale (UHDRS) Total…

A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease

Primary Study Objective: The primary objective of this study is to assess the efficacy of laquinimod 0.5 mg and 1.0 mg qd in patients with HD after 12 months of treatment using the UHDRS-TMS.Secondary Study Objectives:• To assess the effect of…

The Park-in-Shape study: a randomized controlled trial evaluating the effects of exercise on motor and non-motor symptoms in Parkinson*s disease.

Objectives: To evaluate whether aerobic exercise leads to clinically relevant improvements in 1) motor and 2) non-motor symptoms as well as quality of life and physical fitness.

The effect of glycopyrronium bromide on hypersalivation in patients with Parkinson's disease: a randomised, cross-over, double-blind, placebo controlled trial.

The aim of this study is to prove the efficacy of 3 times daily 1 mg glycopyrronium bromide versus placebo in patients with PD with hypersalivation. Furthermore, the safety of glycopyrronium bromide used in the mentioned dosage will be further…

Botulinum toxin as a new treatment modality for jerky psychogenic movement disorders: a monocenter randomized controlled trial

To evaluate the effect of treatment with BoNT on psychogenic jerks.

Improving cognitive functioning in Parkinson*s disease with transcranial Direct Current Stimulation (PD-tDCS)

Determine the efficacy of atDCS as compared to ctDCS and sham stimulation in the improvement of executive functioning in PD-MCI.

Randomized, double-blind, placebo-controlled trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson*s disease patients with refractory visual hallucinations

To investigate the efficacy of continuous subcutaneous apomorphine infusion compared to placebo in PD patients with visual hallucinations.

A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington*s Disease.

Part 1:Primary Objective- To assess the safety and tolerability of SBT-020 in early stage HD patients. Secondary Objective- To investigate the effect of SBT-020 on mitochondrial function, measured by dynamic 31P-MRS in calf muscles of early stage HD…

The Dutch Parkinson GBA Ambroxol trial (DUPARG-AMBROXOL):
A randomised, double-blind, placebo-controlled, single-center trial with Ambroxol in Parkinson patients with a GBA mutation

The primary objective is to compare the effectiveness of ambroxol versus placebo on the MDS-UPDRS part III motor sub-score in the *practically defined OFF-medication state* in patients with moderate PD, carrying a GBA mutation. The hypothesis is…

A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson*s Disease

The main objective of PD0053 is to provide POC for the efficacy of the ASYN misfolding inhibitor UCB0599 in reducing disease progression in study participants with early-stage PD, and to instruct later stage development. The ultimate goal is to…

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled
Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson*s Disease

This study has been transitioned to CTIS with ID 2023-505645-12-00 check the CTIS register for the current data. Main objective: To evaluate the efficacy of BIIB122 225 mg compared with placebo.Secondary objective: To evaluate the efficacy, safety…

Fecal Microbiota Transplantation for Parkinson*s Disease: a pilot study

Primary objectives: 1. Assess the feasibility of FMT in PD patients.2. Assess the safety of FMT in PD patients. Secondary objectives:1. Explore whether FMT leads to alterations in motor complications (fluctuations or dyskinesias) and PD symptoms in…

Conservative iron chelation as a disease-modifying strategy in Parkinson*s disease

Objectives The main objective of the FAIR-PARK II trial is to demonstrate an effect of DFP on the course of PD (including both disease-modifying and symptomatic effects). The trial's overall objective can be summarized as follows: to…

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of NBI-827104 in Subjects with Essential Tremor.

- To evaluate efficacy of NBI-827104 in subjects with ET - To evaluate safety and tolerability of NBI-827104 in subjects with ET- To evaluate pharmacokinetics of NBI-827104 and metabolite (if quantified) for each treatment in subjects with ET

A randomized phase 1b/2a trial of the effectiveness of intermittent hypoxia interventions in Parkinson*s disease

To explore the safety, feasibility and net symptomatic effects of multiple intermittent hypoxia intervention sessions in individuals with PD. Secondary outcomes include exploring induction of relevant neuroprotective pathways as measured in serum.

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OF PTC857 IN ADULT SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (CARDINALS)

This study has been transitioned to CTIS with ID 2023-510317-26-00 check the CTIS register for the current data. To evaluate the efficacy of PTC857 in reducing disease progression in subjects with amyotrophic lateral sclerosis (ALS)

The HEADS-Up Trial: Sleeping in a head-up tilt position to treat orthostatic hypotension, supine hypertension and nocturia in Parkinson's disease

To assess the efficacy and tolerability of HUTS with different angles, leading to optimal implementation strategies of HUTS to alleviate the impact of orthostatic hypotension and supine hypertension in PD

A randomised, placebo-controlled, multicentre phase IIb study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinson*s disease

Primary:To evaluate the effects of pirepemat on falls frequency as compared to placebo.Secundary:To evaluate the effects of pirepemat on Parkinson's disease motor symptoms as compared to placebo.To evaluate the effects of pirepemat on apathy as…

Slow-SPEED-NL: Slowing Parkinson's Early through Exercise Dosage-Netherlands

The primary objective is to determine the feasibility of a remote intervention study to promote physical activity in people with iRBD. The secondary objectives are to determine the longitudinal effect of an exercise intervention in people with iRBD…